The variable-region peptide sequence and steady-state kinetic behavior are compared for a family of catalytic antibodies that arose from the same immune response to a transition-state analog. The crystal structure of the most catalytically active member of the family (17E8) has been solved to 2.5 A resolution and shows that the antibody active site contains a SerH'"-HisH35 (H = heavy chain) catalytic dyad analogous to-the Ser-His-Asp catalytic triad of serine proteases. The variable-region peptide sequence of the next most active antibody (29G11) differs from that of 17E8 by nine heavy-chain point mutations, and results from computer modeling suggest that the three-dimensional structure of 29G11 is similar to that of 17E8. In addition, 29G11 is an efficient catalytic antibody; it possesses 26% of the hydrolytic activity of 17E8. There is one active-site mutation in 29G1l compared to 17E8; position 99 of the heavy chain of 29G11 contains a glycine residue in place of the nucleophilic serine at this position in 17E8. Consistent with this mutation, results from pH-rate studies and hydroxylamine partitioning experiments indicate that in contrast to the catalytic mechanism of 17E8, the mechanism of 29G11-catalyzed esterolysis does not feature nucleophilic catalysis.
active site contains a SerH'"-HisH35 (H = heavy chain) catalytic dyad analogous to-the Ser-His-Asp catalytic triad of serine proteases. The variable-region peptide sequence of the next most active antibody (29G11) differs from that of 17E8 by nine heavy-chain point mutations, and results from computer modeling suggest that the three-dimensional structure of 29G11 is similar to that of 17E8. In addition, 29G11 is an efficient catalytic antibody; it possesses 26% of the hydrolytic activity of 17E8. There is one active-site mutation in 29G1l compared to 17E8; position 99 of the heavy chain of 29G11 contains a glycine residue in place of the nucleophilic serine at this position in 17E8. Consistent with this mutation, results from pH-rate studies and hydroxylamine partitioning experiments indicate that in contrast to the catalytic mechanism of 17E8, the mechanism of 29G11-catalyzed esterolysis does not feature nucleophilic catalysis. The idea that antibodies with affinity for transition states would show enzyme-like behavior was first postulated in 1969 by Jencks (1) , and a new experimental field was born in 1986 with seminal independent reports of the first catalytic antibodies from the laboratories of Schultz (2) and Lerner (3) . During the past 8 years, the major focus of research in the field has been to define the scope of chemical reactions that are subject to catalysis by antibodies. These efforts have shown that the scope is indeed broad (4); nearly 100 antibodies have been characterized that catalyze a wide variety of chemical reactions, including a number of pericycic processes (5) and difficult transformations that are kinetically unfavorable in the absence of the antibody catalyst (6) . Recently there has been an increase in research activity aimed at understanding the structure-function relations of antibody catalysis (7) (8) (9) (10) (11) (12) . One of the goals of these studies is to acquire sufficient insight into the mechanisms of catalytic antibodies such that improvements in hapten design can be made and that improvements in the activity of first-generation catalytic antibodies may be engineered.
We have reported studies on a catalytic antibody with esterolytic properties (13) . The antibody, 17E8, was raised to the norleucine phosphonate hapten 1 and catalyzes the Lenantioselective hydrolysis of formyl norleucine phenyl ester 2 (Fig. IA) . The catalysis by 17E8 is efficient and exhibits a bell-shaped pH dependence. Results from steady-state hydroxylamine partitioning experiments lend support to a catalytic mechanism involving rate-limiting formation of a covalent acyl-antibody intermediate. In addition, we have solved the crystal structure of the 17E8-1 complex to 2.5 A resolution ( Fig. 1B) (14) . Based on the kinetic and structural data for 17E8, we have proposed a catalytic mechanism that is similar to that of protease and esterase enzymes that feature the conserved active site Ser-His-Asp catalytic triad (15) . In this mechanism we propose that the phenolic hydroxyl of the tyrosine residue at position 101 of the heavy chain (TyrH10l) acts as a pH-sensitive switch; ionization of the TyrHl0l phenolic proton eliminates a hydrogen bond between TyrHlOl and SerH99, allowing rotation to occur about the SerH99 Ca -C bond. A 1800 rotation places the hydroxyl of SerH" within hydrogen-bonding distance of His"35 and within a distance appropriate for nucleophilic attack (3.0 where kcat(obs) = the observed kcat, ko = the maximum kcat achieved if all of the antibody is in the active (singly protonated) form, and pKai and pKa2 are the acidic and basic pKa values of the antibody ionizable groups, respectively. The pH-rate data were fit to this equation using the KALIEDA-GRAPH plotting program (Synergy Software, Reading, PA).
Hydroxylamine Partitioning Studies. The hydroxylamine partitioning behavior of 17E8 and 29G11 was analyzed at the pH corresponding to maximum activity for each antibody (pH 9.5 for 17E8, pH 9.0 for 29G11). This analysis was performed analogously to our previously described method, and the partitioning data for 17E8 (substrate 2, R = acetyl) was obtained in our previous study (13) . For the 29G11-catalyzed reaction, the following stock solutions were freshly prepared prior to the experiments: 50 mM ester 2 (R = formyl) in acetonitrile; 29G11 in PBS (3.6 mg/ml); pH 9.0 buffer (50 mM Ches/150 mM NaCl, pH 9.0); 250 mM NH2OH in pH 9.0 buffer; 1.0 M trifluoroacetic acid in water; 10% (wt/vol) FeCl3 in 0.2 M HCI. Hydroxaminolysis reactions were initiated by adding 0-60 ,ul of the hydroxylamine stock solution to a 1.0-ml cuvette followed by 20 ,ul of the antibody solution. The pH 9.0 buffer was added to a final volume of 480 ,u, and the cuvette was incubated for 3 min at 24.5°C. The substrate 2 stock solution (20 ,ul) was added to the cuvette, and the reactions were run to 10-20% conversion as judged by phenol generation (A270).
After this time, the reaction was immediately quenched by adding 50 ,ul of trifluoroacetic acid solution, and hydroxamic acid quantitation was performed. Background (buffer) reaction rates with no added antibody were performed analogously at each hydroxylamine concentration. Hydroxamic acid quantitation was performed by adding 100 ,ul of the FeCl3 solution to the quenched reaction mixture and incubating the resulting solution for exactly 5 min at 24.5°C. The optical density was then measured at 520 nm. The amount of hydroxamic acid product 4 (see Fig. 5 ) was calculated from a standard curve prepared using a range of concentrations of authentic 4 with the same procedure.
Modeling of 29G11 Structure. The INSIGHT II program (Biosym Technologies, San Diego) was used to generate the modeled structure of 29G11 (see Fig. 3 ). Starting from the structure of 17E8, the corresponding amino acids were mutated to those in the 29G11 sequence. The side chain of the mutated amino acids were adjusted by the auto-rotamer algorithm in INSIGHT II, which checks for collisions and evaluates the energy of the local nonbonded contacts around the regions of the preferred rotamers. The energies of the mutated residues were analyzed and were found to reside in positions of lower energy compared to those in 17E8. The combined valence force field was used for this calculation.
RESULTS
Catalysis of Norleucine Phenyl Ester Hydrolysis. A comparison of the hydrolytic activity for the four related catalytic antibodies 17E8, 29G11, 22H12, and 32H11 is shown in Table  1 . Each antibody showed enantioselectivity for the (S)-enantiomer of substrate 2; 17E8 was the most active catalytic antibody in the series. The other three catalytic antibodies 29G11, 22H12, and 32H11 possess 26%, 3%, and 8%, respectively, of the activity (k,,at) of 17E8 at pH 9.5. The norleucine phosphonate transition state analog hapten 1 competitively inhibits the catalysis of each of the catalytic antibodies.
Variable-Region Sequences of the Catalytic Antibodies. The light-and heavy-chain variable-region sequences of the four catalytic antibodies are shown in Fig. 2 . The two most active clones, 17E8 and 29G11, possess 10 amino acid residues in their heavy-chain complementarity-determining region (CDR) 3 while the two least active clones 22H12 and 32H11 have heavy-chain CDR3 loops that are 13 residues long. There are no analogous insertion/deletion mutations in the lightchain variable regions of the four antibodies; each clone has a light chain that is 104 amino acids in length and CDR loops 1, 2, and 3 consisting of 11, 7, and 8 residues, respectively. Moreover, the light chain variable region sequences of the two most active clones 17E8 and 29G11 are identical, as are the light chain variable regions of the two least active clones, 22H12 and 32H11.
The heavy-chain variable region of 29G11 differs from that of 17E8 by nine point mutations. A model of the 29G11 structure was built based on the three-dimensional structure of 17E8 (Fig. 3) . This model reveals that five of these mutations (I28T, R40K, V66G, S103R, and Y1O5N) are on the solventexposed surface of the 29G11 heavy chain. Two mutations, Y60N and F95L, are in the interior hydrophobic core. These mutations replace aromatic side chains in 17E8 by shorter nonaromatic side chains in 29G11. The two mutations leave a four-atom hole, which may cause a compensatory side chain and main chain collapse in this region (17) . However, these two mutations are located 16 A away from the active site SerH99 in 17E8 (GlyH99 in 29G11). Therefore, it is likely that these mutations will have negligible effect on the modeled active site structure of 29G11. The final two mutations, S99G and A33V, reside in (S99G) and next to (A33V) the 29G11 active site and appear to be a structurally complementary pair. Elimination of the hydroxymethyl side chain in the S99G mutation creates a hole, which is filled in a compensatory manner by y-methyl group of valine with the A33V mutation. pH-Rate Dependence and Hydroxylamine Partitioning of 29G11 and 17E8. The two most active catalytic antibodies 17E8 and 29G11 both show a bell-shaped pH dendence on the catalyzed rate of hydrolysis with ester 2 (Fig. 4) . These data for both antibodies can be fit with excellent statistical agreement to a rate equation based on the presence of two ionizable residues in the antibody that mediate catalysis (13) . A similar bell-shaped pH-rate profile affording the same pK. Catalytic antibody 17E8 catalyzes hydroxaminolysis significantly faster than the buffer-catalyzed reaction as is shown in Fig. 5 . We have previously shown that the rate of catalytic turnover (as measured by phenol production) is unaffected by varying the hydroxylamine concentration (13) . Together these data are consistent with a mechanism featuring rate-limiting formation of a covalent acyl intermediate. erated above that which arises from the uncatalyzed buffer reaction (Fig. 5) .
DISCUSSION
Two previous reports on catalytic antibody sequence-activity relations have shown that catalytic antibodies arising from the same immunization tend to have high variable-region sequence similarity. Martin and coworkers (18) have reported sequence-activity relations for five catalytic antibodies from the same immune response that catalyze phenyl acetate hydrolysis, and Fujii and coworkers (19) have found high sequence similarity in the variable regions of a series of five hydrolytic antibodies also arising from the same immune response. Because we identified four catalytic antibodies from a single immunization with hapten 1, we undertook a similar study of the sequence-activity relations for our catalytic antibody series. In addition, the crystal structure of the most catalytically active member of this family (17E8) (14) allowed for analysis of the catalytic properties of the series in terms of three-dimensional structure.
The major structural difference between the two most active and two least active antibodies is the size of the heavy-chain CDR3 loop. The less active pair of antibodies contain 13 residues in CDR3, whereas the more active pair contain a shorter, 10-residue CDR3 loop. It is worthwhile to compare the structure-activity profiles of the two most active catalytic antibodies in the series, 17E8 and 29G11, because both antibodies contain identical light chains and heavy-chain variable domains that differ by only nine point mutations. Modeling the sequence of 29G11 on the structure of 17E8 (Fig. 3) shows that most of the mutations are solvent exposed, and mutations in the interior of the structure are either complementary or remote from the active site. It is therefore likely that the three-dimensional structures of 17E8 and 29G11 are very similar and that both antibodies bind hapten 1 and substrate 2 in the same way.
There is only one mutation in the active site of 29G11 (at position 99) compared to the 17E8 structure, and this mutation bears directly on the proposed catalytic mechanism for 17E8 (Fig. 6A) . In 17E8, the amino acid at position 99 of the heavy chain is a serine, whereas in 29G11 position 99 is occupied by a glycine. We have proposed that SerH99 in 17E8 functions in catalysis as a nucleophile to form an acyl-antibody intermediate in analogy to the reactive serine residue in the catalytic triad of serine proteases (14) . In the crystal structure of the 17E8-1 complex (Fig. 1B) obtained at pH 7.5, the Oy of SerH99 is oriented away from the bound phosphonate by a hydrogenbonding interaction with TyrHOl1. We have proposed that the pKa 9.1 ionization event that increases k,1t by 35-fold corresponds to the ionization of the TyrHlOl phenolic hydroxyl. We suggest that this deprotonation eliminates the hydrogen bond between TyrH0l1 and SerH99 and triggers rotation about CO-CO bond of SerH99. A 180°rotation about C"--CO places the Oy of SerH99 3.0 A from the phosphorous atom of 1 and also within hydrogen-bonding distance of HisH35, thereby creating an active-site arrangement that resembles two of the three components of the catalytic triad of serine proteases. The antibody 29G11 lacks a functional group at position 99 in the active site and serves as a test for this mechanistic proposal.
Consistent with this proposal, the catalytic properties of 29G11 are different from those of 17E8. First, 29G11 is 4-fold less active than 17E8, suggesting that the presence of an active-site serine is beneficial for catalysis. Second, the acidic limb of the pH-rate profile of 29G11 catalysis is shifted one pK. unit toward neutral pH compared to the 17E8 profile (Fig.   4 ). For 17E8, maximum activity is achieved at pH 9. Proc. NatL Acad Sci USA 92 (1995) lack of antibody-catalyzed hydroxaminolysis for 29G11 argues that a covalent acyl-antibody intermediate is not involved in the hydrolytic mechanism of this antibody.
We conclude from these experiments that 29G11 catalyzes ester hydrolysis by a mechanism that is different from that of 17E8. The data are consistent with a mechanism that involves general base-catalyzed attack of water at the substrate carbonyl to generate a charged, tetradedral intermediate that is stabilized by the protonated form of LysH97 (Fig. 6B) . It is possible that this general base is the active-site HiSH35 and that the acidic limb of the pH-rate profile is a titration of the protonation state of this residue. An alternative mechanism consistent with the present data involves direct attack of hydroxide at the bound substrate carbonyl with stabilization of the developing oxyanion by LysH97 (Fig. 6C) . The fact that 29G11 catalysis does not appear to involve covalent intermediate formation and that the only active-site mutation in 29G11 compared to 17E8 is the substitution of GlyH99 for SerH99 provides additional support for our proposal that SerH99 functions as a nucleophile in 17E8-catalyzed hydrolysis. Moreover, the two antibodies, 29G11 and 17E8, are examples of the versatility of antibody catalysis where two efficient catalysts with different catalytic mechanisms can be obtained from immunization with a single transition-state analog.
